AN2 Therapeutics Inc (ANTX)
2.39
-0.01
(-0.42%)
USD |
NASDAQ |
May 01, 16:00
2.48
+0.09
(+3.77%)
Pre-Market: 09:23
AN2 Therapeutics Cash from Financing (TTM): 84.99M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 84.99M |
September 30, 2023 | 85.32M |
June 30, 2023 | 19.24M |
March 31, 2023 | 7.367M |
December 31, 2022 | 70.36M |
Date | Value |
---|---|
September 30, 2022 | 69.39M |
June 30, 2022 | 69.16M |
March 31, 2022 | 61.98M |
December 31, 2021 | 78.54M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
7.367M
Minimum
Mar 2023
85.32M
Maximum
Sep 2023
60.70M
Average
69.39M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Gilead Sciences Inc | -5.08B |
QuidelOrtho Corp | -265.80M |
CymaBay Therapeutics Inc (DELISTED) | 345.77M |
Insmed Inc | 168.44M |
Revance Therapeutics Inc | 136.57M |